VLON Vallon Pharmaceuticals Inc.

FDA Catalyst Company
0.59
+0.03  (+6%)
Previous Close 0.56
Open 0.55
52 Week Low 0.49
52 Week High 10.36
Market Cap $3,997,091
Shares 6,812,836
Float 1,824,513
Enterprise Value $-2,572,015
Volume 187,699
Av. Daily Volume 4,456,868
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/22/2021

Latest News

  1. PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,700,000 shares of its common stock, at a purchase price of $1.0632 per share.

    Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

    The closing of the sale of the securities in the financing is expected to occur…

    View Full Article
  2. PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported additional results from the SEAL study evaluating the abuse potential of ADAIR.

    ADAIR is the Company's proprietary abuse-deterrent formulation of immediate-release dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

    In March 2022, the Company reported topline results from its SEAL study (Study to Evaluate the Abuse Liability, Pharmacokinetics…

    View Full Article
  3. PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the Japan Patent Office has granted Patent No. 7054709 titled, "Abuse Deterrent Formulations of Amphetamine," covering ADAIR1, the Company's proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.

    David Baker, President & Chief Executive Officer of Vallon commented, "The Japanese market is one of the fastest growing markets for prescription ADHD medications. Historically, there has been…

    View Full Article
  4. PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended March 31, 2022 and provided a corporate update.

    "The first quarter of this year proved to be challenging for Vallon with the unexpected, disappointing topline results from our pivotal SEAL study evaluating ADAIR. The Vallon team, along with our scientific and strategic advisors is currently working to determine the best path forward for the development program," commented…

    View Full Article
  5. Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced it has engaged Ladenburg Thalmann & Co. Inc. ("Ladenburg") to evaluate strategic alternatives for the Company with the goal of maximizing shareholder value.

    Ladenburg has been engaged to advise Vallon on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. This process…

    View Full Article
View All Vallon Pharmaceuticals Inc. News